Ocugen 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ocugen said all three of its late-stage modifier gene therapy programs are now in Phase 3 and that it remains on track to file three BLAs by 2028.
- The company completed enrollment of 140 patients in the OCU400 Phase 3 LIMELIGHT trial; top-line data are expected in the first quarter of 2027.
- Ocugen completed an exclusive OCU400 license agreement with Roots Pharmaceutical for the Middle East and North Africa, eligible for up to $4 million in combined upfront and potential initial development milestone payments, up to $255 million in potential sales milestones, and a 22% royalty on net sales; Ocugen will manufacture commercial supply.
- OCU400 received provisional approval and priority designation in the Bahamas under LARTA, and Ocugen said it is preparing for full approval and potential patient enrollment as early as year-end.
- Ocugen continued its Phase 2/3 GUARDIAN trial of OCU410ST for Stargardt disease, with top-line data anticipated in the second quarter of 2027.
- The first patient was dosed in the OCU410 Phase 3 ARMADA-3 trial for geographic atrophy; the 237-subject study randomizes patients 2:1 to a single subretinal injection or untreated control and has a primary endpoint of GA lesion growth over 12 months.
- As of September 30th, 2026, cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million, and common shares outstanding totaled 339.3 million.
- For the 3 months ended September 30th, 2026, total operating expenses were $19.7 million, including research and development expenses of $12.5 million and general and administrative expenses of $7.2 million; net loss per common share was $0.01, compared with $0.07 for the 3 months ended September 30th, 2025.
- For the 9 months ended September 30th, 2026, total operating expenses were $57 million, including research and development expenses of $34.4 million and general and administrative expenses of $22.6 million; net loss per common share was $0.14, compared with $0.17 for the 9 months ended September 30th, 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to Ocugen's third quarter 2026 financial results and business update. All participants are currently in listen-only mode. Following the speaker's commentary, there will be a question-and-answer session. I will now turn the call over to Chris Clark, Ocugen's VP of Communications.
You may begin. Thank you, operator, and good morning, everyone.
Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress. Rita Johnson-Greene, our Chief Financial Officer, is also on the call to provide a financial update for the quarter ended September 30, 2026. Dr. Mohamed Genead, our Chief Medical Officer, Dr. Arun Upadhyay, our Chief Scientific Officer, and Abhi Gupta, Executive Vice President of Commercial and Business Development, will be available to answer questions following the presentation. This morning, we issued a press release covering our business and operational highlights for the third quarter of 2026. We encourage listeners to review the press release, which is available on our website at ocugen.com.
A replay of this call, along with the slide presentation, will be available on the investors section of the Ocugen website. Before we begin, please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory timelines, commercialization strategy, international expansion, and financial information, and our anticipated cash runway. These statements reflect management's current expectations and are inherently subject to risks, uncertainties, and assumptions that may cause actual results to materially differ from those expressed or implied. We encourage you to review our filings with the Securities and Exchange Commission, including the risk factors detailed therein, for a more comprehensive understanding of these potential risks. Finally, Ocugen's quarterly report on Form 10-Q covering the third quarter of 2026 will be filed today. I will now turn the call over to Dr. Musunuri.
Thank you, Chris, and good morning, everyone. The third quarter was a quarter of execution for Ocugen. We now have all three of our late-stage modifier gene therapy programs in phase III. We advanced our business development strategy, and we established a presence in Europe to support pre-commercial activities. With three phase III programs underway, we're executing against a clear strategy to advance our pipeline and build our global presence through strategic partnerships to bring our therapies to patients around the world. Our modifier gene therapy platform remains the foundation of everything we do. Rather than targeting a single mutation, it is designed to address the underlying biology of complex retinal disease by restoring balance across multiple gene networks. The platform is gene agnostic, it is multifactorial, and it is designed to deliver durable benefit from a single one-time injection.
That approach is what allows us to advance one platform across three major causes of blindness: geographic atrophy, retinitis pigmentosa, and Stargardt disease. We remain on track to file three BLAs by 2028, and our next major milestone is clear. OCU400 is expected to be the first of our phase III programs to read out, with top-line data anticipated in the first quarter of 2027. Let me walk you through the progress made across each program this quarter. I will begin OCU400 in RP, followed by OCU410ST in Stargardt disease and OCU410 in GA before handing the call to Rita for the financial update. In OCU400 for RP, this was an especially productive quarter for the program, with progress on clinical, regulatory, and commercial fronts. On the clinical side, we completed enrollment in our phase III liMeliGhT trial with 140 patients.
Top-line data from the trial are expected in the first quarter of 2027, followed by our planned BLA submission. Our process performance qualification batches are complete, which supports both our BLA and the commercial launch supply of OCU400. On the commercial side, in October, we completed an exclusive OCU400 license deal for the Middle East and North Africa with Roots Pharmaceutical, finalizing the binding term sheet we announced in July. Under the agreement, Ocugen is eligible for up to $4 million in combined upfront and potential initial development milestone payments, up to $255 million in potential sales milestones, and a 22% royalty on net sales, and we will manufacture commercial supply. This is our second regional OCU400 license, following our agreement with Kwangdong Pharmaceutical in South Korea.
On the regulatory and access side, OCU400 received provisional approval and priority designation in the Bahamas under its Longevity and Regenerative Therapies Act, or LARTA. We have executed an agreement with a local partner, the Global Alliance for Regenerative Medicine, to coordinate and manage patient care, and we are progressing site readiness in preparation for full LARTA approval. We are advancing toward potential patient enrollment as early as year-end. This pathway is a meaningful step toward expanding access for RP patients while potentially generating commercial revenues. Taken together, the access pathway in the Bahamas and the Roots license agreement reflect a deliberate strategy. We intend to bring OCU400 to patients in the United States to extend its reach internationally through regional partnerships that add commercial scale without requiring us to build our own infrastructure in every market.
As we build that international reach, we remain focused on the clinical development pathway that will underpin our efforts to bring OCU400 to patients in major markets. Our phase I/II experience also provides important context for the phase III liMeliGhT study. In a post-hoc analysis of seven phase I/II subjects meeting phase III eligibility criteria, five of seven treated eyes, or 71.4%, are projected to meet the phase III responder threshold of at least a two-level improvement on the LDNA scale from baseline at week 52. LDNA measures functional vision with a wider range and finer resolution than the mobility test used in phase I/II, addressing the ceiling effect seen in that study. Our previously reported three-year follow-up adds a longer-term perspective.
Seven out of eight evaluable consented treated subjects, or 88%, showed improvement or preservation of LLVA compared with untreated eyes at year three, with no serious adverse events related to OCU400 reported through three years. Separately, our phase III power analysis shows that even at hypothetical treatment responder rate of just 20% compared with 1% in untreated controls, the model estimates 93.2% power to detect a difference on the primary endpoint. We believe these data support both the design of liMeliGhT and the potential of OCU400, and we look forward to top-line results in the first quarter of 2027. Turning to OCU410ST for Stargardt disease, a pediatric-onset retinal disorder for which there are no approved therapies. We continue to advance our pivotal phase II/III GARDian3 trial per protocol, and we anticipate top-line data in the second quarter of 2027, with a BLA submission to follow.
Finally, OCU410 for GA, an advanced form of dry age-related macular degeneration and our largest commercial opportunity. This quarter marked an important transition for the program into phase III. In September, we announced the first patient dosed in ArMaDa3, our global phase III clinical trial. We plan to complete trial enrollment next year, with a target BLA filing in 2028. ArMaDa3 is a 237-subject study that randomizes patients two to one to a single subretinal injection of OCU410 or to untreated control across the United States, Canada, and Europe. The primary endpoint is GA lesion growth over 12 months. This is the first pivotal gene therapy trial in geographic atrophy. Today's approved GA therapies target a single pathway and require ongoing intravitreal injections as often as monthly. OCU410 is designed to address multiple pathways underlying the disease with a single one-time treatment.
We believe that combination of mechanism and durability gives OCU410 a clear competitive advantage. Here is a snapshot of the market opportunity across our three late-stage development programs. While OCU410 for GA represents our largest commercial opportunity, we believe all three programs have the potential to generate significant revenue while addressing areas of substantial unmet medical need. With that, I will turn the call over to Rita for the financial update.
Rita? Thank you, Shankar. Good morning, everyone.
Our cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30th, 2026. We expect this balance to support our cash runway into 2028, which funds two of our three late-stage programs through their anticipated BLA filings. We had 339.3 million shares of common stock outstanding as of September 30th, 2026. Total operating expenses for the three months ended September 30th, 2026 were $19.7 million and included research and development expenses of $12.5 million and general and administrative expenses of $7.2 million. This compared to total operating expenses for the three months ended September 30th, 2025 of $19.4 million, which included research and development expenses of $11.1 million and general and administrative expenses of $8.2 million.
Ocugen reported a $0.01 net loss per common share for the three months ended September 30, 2026, compared to a $0.07 net loss per common share for the three months ended September 30, 2025. Total operating expenses for the nine months ended September 30, 2026 were $57 million and included research and development expenses of $34.4 million and general and administrative expenses of $22.6 million, compared to total operating expenses for the nine months ended September 30, 2025 of $50.5 million that included research and development expenses of $29.1 million and general and administrative expenses of $24.4 million. Ocugen reported a $0.14 net loss per common share for the nine months ended September 30, 2026, compared to a $0.17 net loss per common share for the nine months ended September 30, 2025. That concludes my financial update.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
